The case involved a clinical trial of Akero's only product, a drug candidate aimed at treating a liver disease. It's the ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

What happenedShares of Akero Therapeutics (NASDAQ: AKRO) were down more than 70% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare ...

Akero Therapeutics' share price is tanking after biotech's NASH drug fails to meet its primary endpoint in a Phase 2B study. Find out why AKRO stock is a Buy.

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the ...

Akero Therapeutics, Inc. is set to hold an investor webcast on January 27, 2025, at 8:00 a.m. ET to present preliminary topline results from its SYMMETRY study, which evaluates the efficacy of ...

Explore Akero Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for AKRO. The bear market induced by the Federal Reserve’s monetary tightening ...

In the last 3 months, 6 analysts have offered 12-month price targets for Akero Therapeutics. The company has an average price target of $62.67 with a high of $83.00 and a low of $33.00.

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious metabolic diseases, particularly non-alcoholic ...

Akero Therapeutics (NASDAQ: AKRO) announces the pricing of an underwritten public offering of 11 million shares of its common stock at a public offering price of $29.00 a share, for an expected ...

Akero Therapeutics Inc has a consensus price target of $68.22 based on the ratings of 11 analysts. The high is $109 issued by UBS on January 31, 2025. The low is $38 issued by Evercore ISI Group ...